There are many ways to treat and manage conditions like overactive bladder (OAB). But could a market brouhaha over neuromodulation IP impact how practitioners leverage established treatments?

The two main players in the field, Medtronic and Axonics, have been butting heads for a while. Both are determined to dominate the OAB treatment market segment that could always use more attention, and the winner will likely be the company that is most innovative over the longer-term. The battle is truly one of “David versus Goliath”.  Here's what the battle for the OAB neuromodulation crown might mean for urology and urogynecology practices.